{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:13:56Z","timestamp":1788956036777,"version":"build-2803163510"},"reference-count":37,"publisher":"National Academy of Sciences","issue":"37","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:p>The 2026 Lasker~DeBakey Clinical Medical Research Award has been awarded to Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa (Chugai Pharmaceuticals, Tokyo, Japan) for invention of a bispecific antibody that joins blood clotting Factors IXa (FIXa) and X (FX), restoring deficient Factor VIII (FVIII) activity in patients with hemophilia A and preventing severe bleeding in this hereditary disorder. Starting from the 1960s, types of FVIII-replacement therapy remarkably improved on-demand hemostatic treatment for ongoing bleeds and enabled prophylactic reduction of bleeding episodes. However, these agents required burdensome intravenous infusions multiple times per week, and ~30% of patients developed neutralizing anti-FVIII antibodies (FVIII inhibitors). To address these unmet medical needs, in 2000, Hattori\u2014a molecular and hematology biologist, Kitazawa\u2014a hematology biologist and translational researcher, and Igawa\u2014a biochemist and protein engineer, conceived, designed, and created over the span of 10 y a novel FVIII-mimetic. Instead of a native protein construct, they engineered a bispecific IgG antibody against FIXa and FX, circumventing the need for FVIII and enabling subcutaneous administration up to once per month. Importantly, they identified the biophysical requirements for the bispecific to mimic FVIII function effectively and safely, and their breakthrough protein engineering design made possible favorable pharmacokinetics and physicochemical properties with efficient manufacturability. Their collective research efforts demonstrate how imagination, determination, and multidisciplinary scientific research come together to improve patients\u2019 lives.<\/jats:p>","DOI":"10.1073\/pnas.2622459123","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:00:21Z","timestamp":1788955221000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":0,"title":["Discovery and development of a bispecific antibody for the treatment of hemophilia"],"prefix":"10.1073","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-0733","authenticated-orcid":false,"given":"William","family":"Pao","sequence":"first","affiliation":[{"name":"Revelio Therapeutics Inc","place":["New York"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_3_4_2_2","volume-title":"StatPearls","author":"Mehta P.","year":"2023","unstructured":"P. Mehta, A. Reddivari, \u201cHemophilia\u201d in StatPearls (StatPearls Publishing, Treasure Island, FL, 2023)."},{"key":"e_1_3_4_3_2","first-page":"69","article-title":"An account of an hemorhagic disposition existing in certain families","volume":"20","author":"Otto J. C.","year":"1808","unstructured":"J. C. Otto, An account of an hemorhagic disposition existing in certain families. Med. Phys J. 20, 69\u201372 (1808).","journal-title":"Med. Phys J."},{"key":"e_1_3_4_4_2","volume-title":"Ueber die haemophilie oder die erbliche anlage zu todtlichen blutungen; inaugural-abhandlung","author":"Hopff F.","year":"1828","unstructured":"F. Hopff, Ueber die haemophilie oder die erbliche anlage zu todtlichen blutungen; inaugural-abhandlung (C.W. Becker, Universitats-Buchdrucker, Wurzburg, 1828)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1180660"},{"key":"e_1_3_4_6_2","first-page":"47","article-title":"Haemophilia. A short survey","volume":"39","author":"Macfarlane R. G.","year":"1931","unstructured":"R. G. Macfarlane, Haemophilia. A short survey. St Bartholomew. Hosp. J. 39, 47 (1931).","journal-title":"St Bartholomew. Hosp. J."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)43846-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI100829"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/202498a0"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.145.3638.1310"},{"key":"e_1_3_4_11_2","volume-title":"BREAKTHROUGH: The Quest for Life-Changing Medicines","author":"Pao W.","year":"2024","unstructured":"W. Pao, BREAKTHROUGH: The Quest for Life-Changing Medicines (Oneworld Publications Ltd., London, 2024)."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/203312a0"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12042"},{"key":"e_1_3_4_15_2","first-page":"61","article-title":"Hemophilia: An amazing 35-year journey from the depths of HIV to the threshold of cure","volume":"121","author":"White G. C.","year":"2010","unstructured":"G. C. White, Hemophilia: An amazing 35-year journey from the depths of HIV to the threshold of cure. Trans. Am. Clin. Climatol. Assoc. 121, 61\u201373, discussion 74\u201365 (2010).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16311"},{"key":"e_1_3_4_17_2","unstructured":"T. Pink Sheet Baxter\/Genetics Institute\u2019s recombinate antihemophilic factor approved by FDA dec. 10; first licensed rFactor VIII product will begin shipping Dec. 21. (1992). https:\/\/insights.citeline.com\/PS021887\/BAXTERGENETICS-INSTITUTEs-RECOMBINATE-ANTIHEMOPHILIC-FACTOR-APPROVED-BY-FDA-DEC-10-FIRST-LICENSED-rFACTOR-VIII-PRODUCT-WILL-BEGIN-SHIPPING-DEC-21\/ (Accessed 14 July 2026)."},{"key":"e_1_3_4_18_2","unstructured":"FDA Antihemophilic factor (recombinant). Orphan Drug Designations and Approvals. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=39289."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00025-0"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4838(99)00266-6"},{"key":"e_1_3_4_21_2","first-page":"12","article-title":"Symmetry breaking: Bispecific antibodies, the beginnings, and 50 years on","volume":"12","author":"Riethm\u00fcller G.","year":"2012","unstructured":"G. Riethm\u00fcller, Symmetry breaking: Bispecific antibodies, the beginnings, and 50 years on. Cancer Immun. 12, 12 (2012).","journal-title":"Cancer Immun."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12474"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613023"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2545-9"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0798-677"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_4_31_2","unstructured":"Chugai Chugai\u2019s Hemlibra\u00ae receives the world\u2019s first regulatory approval from FDA for hemophilia A with inhibitors (2017). https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20171117083000_53.html."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_3_4_33_2","unstructured":"Genentech Hemlibra- emicizumab injection solution. FDA Online Label Repository. https:\/\/www.hemlibra-hcp.com\/dosing-and-administration\/dosing.html?c=hea-18a958edaf4&gclsrc=aw.ds&gad_source=1&gad_campaignid=22298991046&gbraid=0AAAAAC7VVofaE5dTym2F4AEhilB1ksOeh&gclid=Cj0KCQjw-frTBhCvARIsADv4XY7N8Zn-ISxvkVZXETld7TCczmeCjA_BChSs1Va8-jThWwjQaDAtCIAaAlKyEALw_wcB."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13618"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102415"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/9783527826872.ch7"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.2622459123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:00:30Z","timestamp":1788955230000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/10.1073\/pnas.2622459123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":37,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["10.1073\/pnas.2622459123"],"URL":"https:\/\/doi.org\/10.1073\/pnas.2622459123","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"2026-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2622459123"}}